Biomarin Pharmaceutical Inc (BMRN)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 595,138 | 593,095 | 1,083,020 | 1,079,080 | 1,075,140 |
| Total stockholders’ equity | US$ in thousands | 5,657,990 | 4,951,550 | 4,603,160 | 4,265,670 | 4,100,930 |
| Debt-to-equity ratio | 0.11 | 0.12 | 0.24 | 0.25 | 0.26 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $595,138K ÷ $5,657,990K
= 0.11
The debt-to-equity ratio of Biomarin Pharmaceutical Inc has shown a decreasing trend over the past five years, indicating a favorable financial position in terms of leverage. The ratio decreased from 0.26 in December 2020 to 0.11 in December 2024. This suggests that the company has been reducing its reliance on debt financing in relation to equity, which can be seen as a positive indicator of financial stability and risk management. A decreasing trend in the debt-to-equity ratio implies that the company is potentially less risky for creditors and investors, as there is a lower level of debt relative to shareholder equity. Overall, the decreasing debt-to-equity ratio reflects a prudent capital structure management by Biomarin Pharmaceutical Inc.
Peer comparison
Dec 31, 2024